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Background: Pharmaceutical care is the direct interaction between pharmacist and patient, in order to improve
therapeutic compliance, promote adequate pharmacotherapeutic follow-up, and improve quality of life.
Pharmaceutical care may be effective in reducing complications and in improving the quality of life of patients with
chronic diseases, like Chagas heart disease, while bringing a positive impact on health system costs. The morbidity
and mortality indexes for patients with Chagas heart disease are high, especially if this heart disease is complicated
by heart failure. In this setting, we hypothesize that pharmaceutical care might be an important tool for the clinical
management of these patients by improving their quality of life, as a better compliance to their treatment and the
avoidance and prompt correction of drug-related problems will minimize their symptoms, improve their functional
class, and decrease the number of hospital admissions. Therefore, the aim of this trial is to evaluate the contribution
of pharmaceutical care to clinical treatment of patients with Chagas heart disease complicated by heart failure.
Methods/design: A prospective, single-center randomized clinical trial will be conducted in patients with Chagas
heart disease complicated by heart failure. A total of 88 patients will be randomly assigned into two parallel groups:
an intervention group will receive standard care and pharmaceutical care, and a control group will receive only
standard care. Both groups will be subjected to a follow-up period of 12 months. The primary outcome of this trial
is the evaluation of quality of life, measured by the 36-item short-form and the Minnesota Living with Heart Failure
Questionnaire. Secondary outcomes include drug-related problems, exercise tolerance as measured by the standard
six-minute-walk test, and compliance.
Discussion: Patients with Chagas heart disease complicated by heart failure under pharmaceutical care are
expected to improve their quality of life, present with a lower incidence of drug-related problems, improve their
functional capacity, and improve in their compliance to treatment.
Trial registration: ClinicalTrials.gov Identifier: NCT01566617
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Chagas disease is still a major public health problem in
Latin America. About 10 million people worldwide are
estimated to be infected with Trypanosoma cruzi, mostly
in Latin America and 20 to 30% of these individuals are
expected to present cardiac complications during their
lifetime [1]. According to the Brazilian Ministry of* Correspondence: gilbertomarcelo@gmail.com
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reproduction in any medium, provided the orHealth, there are still about 2.5 million individuals living
with chronic Chagas disease in Brazil and, in 2009, 4,700
deaths attributed primarily to Chagas disease were
reported in Brazil [2].
Chagas disease has two distinct clinical phases, acute
and chronic [3]. The majority of acute cases are clinic-
ally silent and last for 6 to 8 weeks. Only less than 10%
of acute cases will present a self-limiting febrile illness,
which can be aggravated by acute myocarditis. The acute
phase is followed by a chronic phase, which has threed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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terminate chronic form is a long-lasting asymptomatic
phase, when patients present reactive serologic tests for
Chagas disease but there is no evidence of damage to
any organ [3-5]. However, two or more decades after in-
fection, 20 to 30% of the patients will progress to the
cardiac form of the disease, when the majority of the
deaths and severe complications related to the disease
occur [6-8]. Patients at the chronic cardiac phase may
manifest heart failure (HF), ventricular and atrial
arrhythmias, atrioventricular blocks, thromboembolism,
stroke, and sudden death [8-10], with a high economic
and mortality burden. Another 10 to 15% of the patients
at the chronic phase will present evidence of digestive
disease characterized by complaints of dysphagia or con-
stipation and radiologic evidence of megaesophagus or
megacolon [11]. An unspecified number of patients may
present evidence of a mixed chronic form with evidence
of both cardiac and digestive involvement [9].
Heart failure is a clinical syndrome that arises second-
ary to changes of cardiac structure or function that im-
pair the ability of the left ventricle to fill or eject blood.
The clinical manifestations are dyspnea, fatigue, and
edema with impairment of functional capacity and qual-
ity of life of affected individuals. Heart failure is cur-
rently classified by the American Heart Association into
four stages: A (patients at risk of developing HF); B
(patients who have structural heart disease known to be
associated with HF); C (patients with symptomatic HF);
and D (patients with HF refractory to treatment) [12].
The treatment of patients with chronic Chagas heart
disease is aimed at controlling symptoms and improving
patients’ quality of life, by preventing cardiovascular
complications, limiting disease progression, and increas-
ing the overall survival rate of the patients. Unfortu-
nately, there is no specific treatment against the parasite
that can benefit patients at this stage, and treatment fol-
lows the guidelines issued to treat HF and arrhythmias
due to complications caused by other etiologies [12].
In the proposed trial, we will focus on the contribution
of pharmaceutical care to clinical treatment of patients
with Chagas heart disease complicated by HF. The
pharmacological treatment of patients with chronic
Chagas heart disease complicated by HF includes such
drugs as angiotensin-converting enzyme (ACE) inhibitors
[13] or angiotensin II receptor blockers, beta blockers
[14-18], aldosterone antagonists [18,19], digitalis, and loop
diuretics. Many of these pharmacological strategies can
prolong the life expectancy of patients with HF and are
recommended in patients with Chagas heart disease com-
plicated by HF [9]. Other drugs may be required as spe-
cific HF complications, such as atrial fibrillation, occur.
For example, atrial fibrillation and ventricular arrhythmias
will require drugs such as antiarrhythmics [12,18,20].Another important aspect of HF treatment is the control
of precipitating factors. Precipitating factors are any fac-
tors that can trigger an episode of decompensated HF.
These include poor dietary or medical compliance, in-
appropriate discontinuation or reduction of HF therapy by
the physician, use of medications known to worsen HF, in-
adequately treated hypertension, anemia, arrhythmias, and
acute myocardial ischemia. Poor medical compliance and
use of medications known to worsen HF, such as nonster-
oidal anti-inflammatory drugs, calcium antagonists, thia-
zolidinediones, class I antiarrhythmic agents, and sotalol,
are potentially preventable precipitating factors that can
be minimized by pharmaceutical care [12,21]. Pharma-
ceutical care is a practice performed by the clinical
pharmacist who delivers the patient’s prescription, in order
to improve compliance, avoid underuse of appropriate
drugs and optimize their dosage, avoid use of inappropri-
ate drugs, and detect, prevent, and resolve drug-related
problems (DRPs) [22] and improve the patient’s quality of
life [24]. The value of this strategy has been demonstrated
in distinct clinical scenarios [23-25]. In patients with HF,
this intervention may improve patients’ symptoms, avoid
hospitalizations, and, consequently, improve patients’
quality of life. In fact, small, short-term trials and observa-
tional data suggest that pharmaceutical care intervention
reduces the risk of hospital admission and possibly mortal-
ity in patients with HF [26,27].
Drug-related problems are health problems linked to
drug therapy that may affect expected results of patients’
therapy and their quality of life, while causing a high
economic and mortality burden [28]. In the United
States alone, the annual related costs of DRPs have been
estimated as 177.4 billion dollars [29]. Several factors
may contribute to DRPs, such as access to drug therapy,
noncompliance to drug therapy, prescription duplicity,
ineffectiveness of drug therapy, adverse drug reactions
(ADRs), and dosage above the therapeutic range [30].
Chronic diseases, such as HF, impose a great limitation
on the patients’ quality of life [31] and the success of treat-
ment strategies for HF is measured not only by the increase
in event-free time survival but also by the improvement in
the quality of life of the patient [21]. Pharmaceutical care
may improve a patient’s quality of life related to HF [21]
and it is important to test this hypothesis in patients with
Chagas heart disease complicated by HF, who, in Brazil, are
mostly assisted in public outpatient services. Therefore, our
aim is to evaluate the effect of pharmaceutical care, as com-
pared with standard care, on the quality of life of patients
with Chagas heart disease complicated by HF.
Methods/design
Study design
The proposed clinical trial will be held at a single center,
the Evandro Chagas Clinical Research Institute (IPEC),
Figure 1 General overview of study protocol. 6MWT, six-minute-
walk test; DRPs, drug-related problems; HF, heart failure.
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Oswaldo Cruz Foundation (Fiocruz). IPEC is a 93-year-old
institution fully dedicated to clinical research in infectious
diseases, including Chagas disease, among others. IPEC is
a major reference center for research, care, and training
on Chagas disease.
This is a double-blinded, controlled, superiority (parallel)
clinical trial with balanced randomization [1:1] that will be
conducted for adult volunteers with Chagas disease com-
plicated by HF. The patients’ functional status will be clas-
sified according the New York Heart Association (NYHA)
functional classification system from I to IV. All patients at
our institution are treated following current guidelines for
diagnosis and management of HF in adults [12].
The cardiologists from our outpatient center will refer
patients with chronic Chagas disease complicated by HF
to the pharmacist. The pharmacist will explain the study
in detail and obtain the patients’ informed consent.
All included patients will undergo a screening phase,
which includes a review of the patient’s medical records
and an interview for assessment of eligibility. All eligible
patients will complete quality-of-life questionnaires and
take a six-minute-walk test after inclusion. After the
screening phase, patients will be randomly assigned to
one of two groups: an intervention group, who will re-
ceive standard care plus pharmaceutical care, and a con-
trol group, who will receive only standard care.
Each patient will be followed for 12 months. All
patients from both groups will take part in medical con-
sultations every month. After each medical consultation,
a pharmacist blinded to the patient’s assignment will
interview all patients, to identify compliance to treat-
ment and any DRPs. After this, all patients will interact
with the clinical pharmacist. Those randomized to the
control group will receive all prescription medications,
while those patients randomized to the intervention
group will not only receive all prescription medications
but will also undergo pharmaceutical care, to solve
DRPs, confirm, and reinforce their compliance to the
medical prescription. Whenever the pharmacist identi-
fies a DRP in the intervention group, he will interact
with the physician, to solve the DRP. All patients will
take part in a pharmaceutical consultation at the end of
the follow-up, to identify DRPs, complete quality-of-life
questionnaires, and perform six-minute-walk tests. The
pharmacists who will deliver the initial evaluation before
randomization, the monthly evaluations of DRPs and
compliance, and the final evaluation at the end of the
follow-up period will be blinded to the patients’ assign-
ment (Figure 1).
Patients: inclusion and exclusion criteria
Inclusion criteria are adults (>18 years old), men and
women, with chronic Chagas disease diagnosed by twodistinct Chagas serology tests (indirect immunofluores-
cence and ELISA), and complicated by HF. For the pur-
pose of this study, HF diagnosis will be based on current
or past symptoms compatible with HF and associated with
underlying structural heart disease and left-ventricle ejec-
tion fraction under 55%, as measured by an echocardio-
gram. Exclusion criteria are: any comorbidities that
significantly affect cardiac performance, such as coronary
artery disease, moderate or severe heart valvular disease,
left-ventricle hypertrophy, or congenital heart disease;
comorbidities that limit survival, such as malignant
tumors or HIV; failure to obtain informed consent; inabil-
ity to perform six-minute-walk test; significant cognitive
impairment; pregnancy; concomitant participation in
other intervention trials; or NYHA functional class IV.
Interventions: pharmaceutical care vs. standard care
The pharmaceutical care applied in this trial will be
based on Dáder methodology. The Dáder method for
Silva et al. Trials 2012, 13:244 Page 4 of 7
http://www.trialsjournal.com/content/13/1/244pharmaceutical care is a systematic process developed
by the Research Group of Pharmaceutical Care at the
University of Granada, Spain [32]. This method includes
patient education about cardiovascular drugs, patient
counseling about lifestyle modifications, assessment of
drug compliance, identification of underuse of appropri-
ate drugs, optimization of drug dosage, and identifica-
tion of the use of inappropriate drugs, to enable the
pharmacist to deliver treatment recommendations to
physicians and contribute to relieving DRPs [32] and
improved quality of life [21,23].
Those patients randomized to standard care will re-
ceive all prescription medications from the pharmacist
and basic instruction on how to use them.
Outcomes
The primary endpoint of this trial will be an increase in
the quality of life. Heart disease may impose important
limitations on patients’ daily activities that often affect
their functional and general health status [21]. Quality of
life will be evaluated using the 36-item short-form (SF-36)
[33] and the Minnesota Living with HF Questionnaire
(MLHFQ) adapted by Carvalho et al. [34]. The SF-36 will
be measured in all eight subscales: physical functioning,
physical role, bodily pain, general health, vitality, social
functioning, emotional role, and mental health. The two
summary measures are the Physical Component Summary
and the Mental Component Summary score. Items scores
related to each subscale are coded, summed, and scaled
from 0 (worst possible health state) to 100 (best possible
health state) [23,33,35,36]. The MLHFQ is one of the most
widely used questionnaires to evaluate quality of life of
patients with HF. It is made up of 21 items that cover HF-
related physical, psychological, and social impairments.
The patient’s perception of such impairment is assessed
on a scale ranging from ‘none’ (a score of 0) to ‘very much’
(5). The total MLHFQ score is obtained by adding the
scores for all 21 items (range, 0 to 105), where a higher
score indicates a worse quality of life [37].
The secondary endpoints evaluated will be incidence
and types of DRPs, physical functional capacity, and
compliance. Drug-related problems will be identified
case by case, based on the classification of the Brazilian
Pharmaceutical Care Consensus [38]. They will be classi-
fied by evaluating three distinct criteria of pharmaco-
therapy: indication, effectiveness, and safety [30,38].
Among DRPs, suspected ADRs will be classified accord-
ing to Naranjo’s algorithm [39]. All identified DRPs will
be reported in patients’ medical records. Another sec-
ondary endpoint will be physical functional capacity. All
patients will have their functional capacity measured by
the six-minute-walk test. The test will be performed at
the beginning of protocol and after 12 months of follow-
up. The test will be conducted on three consecutivedays, at the same time and followed by the same evalu-
ator. It will take place along a closed corridor, 33 m long.
Walk tests will be performed at least 2 hours after
patients’ meals. Patients will be instructed by a cardiolo-
gist or designed professional to walk as much as possible
for 6 minutes. Patients will be oriented to adjust their
walking speed between relatively easy and slightly tiring.
The test will measure the maximum distance each pa-
tient can walk in the corridor [40-42]. Patients’ compli-
ance to medical treatment will be measured using self-
reports of medication adherence on the Morisky scale
[43]. This simple four-question survey assesses the likeli-
hood that patients take their medications as prescribed.
The questions will be: ‘Do you forget to take your medi-
cations? Are you careless about the time at which you
take your medications? Do you stop taking your medica-
tions when you feel better? Do you stop taking your
medications when you feel worse?’ Each ‘yes’ answer is
given a score of 1, and each ‘no’ a score of 0. Those
patients scoring 0 will be considered adherent, and those
scoring 1 to 4 will be considered nonadherent [43].
Ethical issues
This study was approved by our local Committee for Eth-
ics in Research (IRB) under the number 0034.0.009.000-11
and is registered at ClinicalTrials.gov under number
NCT01566617 [44]. The IPEC IRB membership includes
multidisciplinary representation as well as community
representation. It is registered at the National Committee
for Ethics in Research-MOH [45] and operates according
to the Brazilian Ethics in Human Research Regulations.
Protection against risk
The informed consent process will be conducted accord-
ing to good clinical practices. The potential study
patients will sign an informed consent form after reading
it, receiving adequate explanations, and understanding
the study objectives and procedures. Illiterate patients
may bring in relatives or friends to read for them, testify,
and sign the consent form: if this is not possible, we can
enroll a patient, and a witness will sign the consent
form. The formal informed consent process will be
accomplished and documented before any other study-
related procedures. Adequate time will be allowed for
the patient to ask questions. All aspects of the study will
be explained to the patients, including, but not limited
to, potential risks and benefits, and the amount of time
required from the patient, including the number of study
visits expected. All patients will be informed that partici-
pation is voluntary, that refusal to participate will involve
no penalty or loss of benefits to which the patient is
otherwise entitled, and that the patient may discontinue
participation at any time without penalty or loss of bene-
fits to which the patient is otherwise entitled.
Table 1 Sample size calculation according to scenarios of






Quality of life, mean
(standard deviation)
52.8 (10.9) 63.1 (10.1)
Significance level 1.0% 1.0%
Power of test 95.0% 95.0%
N 40 patients 40 patients
N + 10% (in each
group)
44 patients 44 patients
Ratio 1:1 1:1
Total 44 44 88
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Patients who miss a scheduled study visit will be con-
tacted by telephone to schedule a new visit. Case report
forms will identify patients only by the study number.
All records identifying patients by name and information
linking patients’ names with study ID numbers will be
kept in locked rooms in locked cabinets and will be ac-
cessible only to study personnel. We will provide
patients with the names and telephone numbers of the
principal investigator and sub-investigators, and they will
be advised that they are allowed to make reverse-charge
telephone calls. Information regarding the patient’s med-
ical history will be obtained with the patient’s consent.
Regarding this proposal, the procedures are considered
to offer minimal risks for the patients. The patients may
derive direct benefits derived from research and the
knowledge acquired may potentially improve the health
care of other patients suffering from Chagas disease.
Therefore, the benefits of this research will fall into two
major categories: benefits to patients and benefits to so-
ciety. Patients will not receive any kind of remuneration,
but will be reimbursed for travel expenses and meals.
Data and safety monitoring plan
The IPEC IRB will reevaluate the research project at
intervals appropriate to the degree of risk but not less
than once a year. Periodic review of the research activity
is necessary to determine whether the risk/benefit ratio
has shifted, whether there are unanticipated findings in-
volving risks to patients, and whether any new informa-
tion regarding the risks and benefits should be provided
to patients. At the time of initial review, the IPEC IRB
will determine whether an independent data and safety
monitoring board or committee will be required, and
should also set a date for reevaluating the research pro-
ject. In light of the risk/benefit ratio reassessment, the
IRB may require that the research be modified or halted
altogether. Alternatively, special precautions or criteria
for inclusion may be relaxed. The principal investigator
and study team will keep the IPEC IRB informed of sig-
nificant findings that may affect the risk/benefit ratio.
The investigators will inform patients of any important
new information that might affect their willingness to
continue participating in the research.
Data collection
At the screening phase, data regarding quality of life,
six-minute-walk test results, DRPs, and clinical and
sociodemographic data will be collected. Clinical and
sociodemographicdata will include age, sex, functional
class, heart rate, blood pressure, weight, Chagas sero-
logical test results, biochemical data (urea, creatinine,
bilirubin, aspartate aminotransferase, alanine amino-
transferase, and alkaline phosphatase levels), andcomorbidities (hypertension, diabetes, and asthma), as
well as alcoholism, smoking, and prescription drugs.
Data about DRPs will be collected at least once a
month. At the end of the study follow-up, DRPs, six-
minute-walk test results and MLHFQ and SF-36 scores
will be collected again.Statistical methods
The EpiData [46] and Statistical Package for the Social
Sciences [47] applications will be used for data entry and
analysis, respectively. The statistical calculations will be
performed on an intention-to-treat basis, where patients
will be analyzed as initially randomized. Continuous vari-
ables will be expressed as mean ± standard deviation. The
Kolmogorov-Smirnov test will be used to test sample dis-
tribution. The analysis strategy will be based on differ-
ences of MLHFQ and SF-36 scores, DRPs outcome, and
six-minute-walk test results between the control and inter-
vention groups. For quality-of-life questionnaires and the
six-minute-walk test, the Student’s t test will be used if
sample distribution proves to be normal. Otherwise, the
Wilcoxon rank-sum test will be used. For DRPs and com-
pliance, cumulative incidence and relative risks will be
estimated with their respective 95% confidence intervals,
and will be used to test differences. The null hypothesis
will be rejected at P < 0.05.Sample size calculation
Sample size calculation was based on previous work of the
literature that evaluated pharmaceutical care and quality
of life in patients with HF [21]. We estimated that 40
patients per group would be needed to detect a difference
in quality of life on SF-36 of 10.3 points, allowing a stand-
ard deviation of up to 10.9 points, one-sided 1% signifi-
cance, and 95% power. As we expect loss during follow-up
of at least 10% of the study participants, 88 participants
(44 per group) will be required (Table 1).
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A computer-generated random list of allocation, to ei-
ther pharmaceutical care or standard care, will be gener-
ated, balancing 1:1. This assignment will occur within
randomly ordered blocks of size four, six, or eight.
The allocation sequence will be concealed from the
researchers enrolling and assessing participants, in se-
quentially numbered opaque, sealed, and stapled envel-
opes. To prevent subversion of the allocation sequence,
the name and date of birth of the participant will be writ-
ten on the envelope before the envelope is opened. The in-
formation in the envelope will be transferred to the
allocation card inside the envelope. Corresponding envel-
opes will be opened only after enrolled participants have
completed all baseline assessments and at the time of allo-
cation. These procedures will be carried out by a profes-
sional without access to baseline evaluation results.
Blinding
The pharmacists who will carry out the initial evaluation
before randomization, monthly evaluations of DRPs, and
compliance, and the final evaluation of the health care
questionnaires after the end of the patient follow-up will
be blinded to the patient’s assigned group. Physicians
conducting the six-minute-walk test will also be blinded
to group assignment.
Discussion
Pharmaceutical care in the treatment of patients with
HF has been associated with significant reductions in
the risk of all-cause hospitalizations and HF hospitaliza-
tions [21,26,27], and with an improvement of exercise
tolerance and quality of life [21]. Those improvements
were related to a higher compliance to prescribed medi-
cations [21] and higher ACE inhibitor doses [27] in the
group of patients who received pharmaceutical care. On
the other hand, Lowrie et al. [48] reported no improve-
ment in the composite endpoint of death from any cause
or hospital admission for worsening HF in patients with
left-ventricle systolic dysfunction when submitted to
pharmacist intervention. However, in this study, the
training of the pharmacists was limited to brief tuition
and the improvements in the prescription of outcome-
modifying medications were, at most, modest.
The present proposed trial will be the first one to
evaluate pharmaceutical care conducted in patients with
HF due to Chagas disease. The population of patients
with Chagas disease are a group of underprivileged indi-
viduals with limited access to health care services and
with a high proportion of illiterate individuals [49].
Therefore, we anticipate that pharmaceutical care inter-
vention in this group of individuals will increase the rate
of compliance to prescribed medications, while helping
to improve the achievement of maximum tolerated doseof outcome-modifying medications and mitigating DRPs.
In consequence, we expect that the intervention group will
experience an improvement in the quality of life and in ex-
ercise tolerance. We expect that the improvement attained
in quality of life, as measured by MLHFQ and SF-36
scores, at the end of 12 months of follow-up will be of at
least ten points. Recently, Kato and colleagues have also
demonstrated that a low MLHFQ score is associated with
increased risk of all-cause death as well as the combined
endpoint of cardiac death or hospitalization for HF in
patients with HF [37], which reinforces the value of the
quality of life score used in this proposed trial.
The confirmation of the expected results in this trial will
be the basis for future larger studies addressing the influ-
ence of pharmaceutical care on mortality outcomes of
patients with Chagas heart disease complicated by HF.
Trial status
This study is currently recruiting patients.
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